Casper Van Eijck News Today

Treatment demonstrated significant survival data in addition to a sustained safety profile - News - PharmaTimes

Special Note Regarding Forward-Looking Statements Certain statements in this Report contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of... | May 13, 2022

Positive results from first cohort of 10 patients from REACtiVe study published in European Journal of Cancer Amphera B.V. announces positive REACtiVe Phase 2 study safety and efficacy data from the

AIM ImmunoTech Inc. AIM ImmunoTech’s Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer AIM ImmunoTech’s Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer OCALA, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its subsidiary, NV Hemispherx Biopharma Europe, has received formal no...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients ... AIM ImmunoTech Inc.February 10, 2021 GMT OCALA, Fla., Feb. 10, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Dutch Health and Youth Care Inspectorate (IGJ) has approved treatment for six pancreatic cancer patients as part of a new, follow-up Early Access Prog...